A Device Strategy-Matched Comparison Analysis among Different Intermacs Profiles: A Single Center Experience

Abstract

Background: The present study evaluates outcomes of LVAD patients, taking into account the device strategy and the INTERMACS profile. Methods: We included 192 LVAD-patients implanted between January 2012 and May 2021. The primary and secondary end-points were survival and major adverse events between Profiles 1–3 vs. Profile 4, depending on implantation strategies (Bridge-to-transplant-BTT; Bridge-to-candidacy-BTC; Destination-Therapy-DT). Results: The overall survival was 67% (61–75) at 12 months and 61% (54–70) at 24 months. Profile 4 patients showed significantly higher survival (p = 0.018). Incidences of acute right-ventricular- failure (RVF) (p = 0.046), right-ventricular-assist-device (RVAD) implantation (p = 0.015), and continuous-venovenous-hemofiltration (CVVH) (p = 0.006) were higher in Profile 1–3 patients, as well as a longer intensive care unit stays (p = 0.050) and in-hospital-mortality (p = 0.012). Twelve-month and 24-month survival rates were higher in the BTT rather than in BTC (log-rank = 0.410; log-rank = 0.120) and in DT groups (log-rank = 0.046). In the BTT group, Profile 1–3 patients had a higher need for RVAD support (p = 0.042). Conclusion: LVAD implantation in elective patients was associated with better survival and lower complications incidence. LVAD implantation in BTC patients has to be considered before their conditions deteriorate. DT should be addressed to elective patients in order to guarantee acceptable results.

Early Postoperative Neurologic Events Are Associated With Worse Outcome and Fatal Midterm Survival After Adult Heart Transplantation

“…They are well established, for example, in the field of left ventricular assist device surgery, where it is used in various recent publications. 20 , 21 , 22 , 23 , 24 …”

Design and Optimization of Coil for Transcutaneous Energy Transmission System

“…Wireless power transfer technology is regarded as an effective solution to ensure stable power supply to artificial hearts while eliminating the need for transcutaneous wires, thereby significantly reducing the risk of infection. The adoption of wireless power transfer technology enhances the freedom and comfort of patients using artificial heart devices, offering them a higher quality of life during treatment [4][5][6].…”

Biventricular assist devices and total artificial heart: Strategies and outcomes

“…The reason for the complexity is that the BHF treatment strategy will be determined with the consideration of support duration for both ventricles. Furthermore, the clinical scenario will be important to determine the device; for example, the device selection may differ with the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) patient profiles and baseline patient characteristics, including the diagnosis (1,2).…”